Recombinant adeno-associated virus transduction and integration.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms without new clinical or experimental data
PubMed 18500252 · doi:10.1038/mt.2008.103
What was done
This narrative review synthesizes the biological mechanisms and rate-limiting steps of recombinant adeno-associated virus (rAAV) transduction, covering virus-cell attachment, intracellular trafficking, nuclear entry, vector genome conformation, and host genome integration.
What was found
The abstract provides no quantitative metrics or numerical values. Qualitatively, rAAV utilizes multiple pathways to achieve transgene expression depending on serotype, dose, and cell type. Intranuclear vector genomes exist predominantly as episomes, leading to stable transduction primarily in nondividing cells, while integration into the host genome occurs at low frequency, often in or near genes, with potential associated host mutations.
Why it matters
Understanding the multi-step transduction biology and integration profiles of rAAV is essential for optimizing vector design, delivery efficiency, and safety in gene therapy applications.
Limits
This is a narrative review without original clinical or experimental data. The abstract provides no quantitative frequencies of integration, comparative serotype data, or specific mutation rates.
Cited by
- supports Adeno-associated virus (AAV) vector DNA does not integrate into human chromosomes in over 90% of cases, instead forming an episome.